proxyvotesnow.com

Home › Companies › Theravance Biopharma, Inc. › 2024-2025

Theravance Biopharma, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Theravance Biopharma, Inc.’s Form 8-K, filed 2025-05-20 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 8Reported items
  • 135Asset managers
  • 937Fund votes
  • 2025-05-19Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Theravance Biopharma, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Theravance Biopharma, Inc.

These tallies are Theravance Biopharma, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Theravance Biopharma, Inc. — official shareholder meeting results, meeting held 2025-05-19
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Rick E Winningham 28,586,1641,965,6949,513,702 --5,680,519 Majority: yes
Elect Director: Jeremy T. Grant 39,915,281145,9694,310 --5,680,519 Majority: yes
Elect Director: Susannah Gray 39,943,074110,83311,653 --5,680,519 Majority: yes
Elect Director: Donal O'Connor 39,871,814180,33513,411 --5,680,519 Majority: yes
Elect Director: Number of Shares Voted 45,165,816578,0702,193 ---- Majority: yes
Elect Director: Number of Shares Voted 30,154,992374,2579,536,311 --5,680,519 Majority: yes

Source: Theravance Biopharma, Inc., Form 8-K, filed with the SEC on 2025-05-20 — read the filing on EDGAR.

How asset managers voted at the Theravance Biopharma, Inc. 2024-2025 meeting

Each item below shows how the 135 asset managers that disclosed a Theravance Biopharma, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Theravance Biopharma, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To vote on a non-binding advisory resolution regarding the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-05-19.

Combines 3 wordings of this item as funds reported it.

99% fund support · no official result

FOR 76%ABSTAIN 23%

The 129 asset managers below cast 99% of the shares they voted on this item FOR (30,810,447 for, 380,057 against).

FOR: 30,810,447 (75.7%)AGAINST: 380,057 (0.9%)ABSTAIN: 9,521,331 (23.4%)
Largest asset managers voting on “To vote on a non-binding advisory resolution regarding the compensation of our named executive officers.” at Theravance Biopharma, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Madison Avenue Partners, LP00 9,511,1500Abstain
Weiss Asset Management LP7,457,0600 00For
Newtyn Management, LLC6,309,4080 00For
Irenic Capital Management LP2,513,5410 00For
Vanguard2,061,3680 00For
BlackRock1,997,5020 00For
Park West Asset Management LLC1,804,2440 00For
Camber Capital Management LP1,000,0000 00For
State Street970,7601,966 00For
GEODE CAPITAL MANAGEMENT, LLC863,0800 00For
DE Shaw860,4840 00For
Fidelity794,9990 00For
Charles Schwab590,7370 00For
Dimensional475,8970 00For
Nuveen374,9520 00For
TIAA373,6580 00For
Northern Trust248,6582,910 00For
Delaware/Macquarie208,7830 00For
American Century0169,942 00Against
Equitable139,8940 00For
Citadel139,4760 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC0131,407 00Against
MELLON INVESTMENTS Corp119,1390 00For
Wellington112,7950 00For
JACOBS LEVY EQUITY MANAGEMENT, INC106,0880 00For

Showing the 25 largest of 129 asset managers. See all 129 in the interactive database.

2. Election of Directors: Donal O'Connor

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-19.

Combines 2 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 39,871,814AGAINST: 180,335

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Donal O'Connor”): 39,871,814 for, 180,335 against, per its Form 8-K filed 2025-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,001,000 outstanding shares: 80% for, 0.4% against (80% of the company cast a for/against vote).

The 41 asset managers below cast 99.9% of the shares they voted on this item FOR (5,693,981 for, 153 against).

FOR 99.9%
FOR: 5,693,981 (100.0%)AGAINST: 153 (0.0%)
Largest asset managers voting on “Election of Directors: Donal O'Connor” at Theravance Biopharma, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,032,7520 00For
BlackRock784,4090 00For
Fidelity784,1260 00For
Dimensional389,4820 00For
TIAA373,6580 00For
Charles Schwab294,8700 00For
Delaware/Macquarie208,7830 00For
Equitable139,8940 00For
American Century84,9710 00For
Columbia Threadneedle62,3110 00For
Lincoln Financial51,5250 00For
SEI42,8670 00For
Global X40,3310 00For
Northern Trust37,3150 00For
ALPS ETF Trust37,2070 00For
ETFis Series Trust I35,4260 00For
Goldman Sachs34,1620 00For
Nationwide30,2550 00For
T. Rowe Price27,1640 00For
QUANTITATIVE MASTER SERIES LLC26,3560 00For
AIG/SunAmerica18,5540 00For
Pacific Life18,3230 00For
GuideStone16,3560 00For
Bridge Builder Trust16,2830 00For
John Hancock14,6810 00For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

3. Election of Directors: Jeremy T. Grant

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-19.

Combines 2 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 39,915,281AGAINST: 145,969

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Jeremy T. Grant”): 39,915,281 for, 145,969 against, per its Form 8-K filed 2025-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,001,000 outstanding shares: 80% for, 0.3% against (80% of the company cast a for/against vote).

The 41 asset managers below cast 99.9% of the shares they voted on this item FOR (5,693,981 for, 153 against).

FOR 99.9%
FOR: 5,693,981 (100.0%)AGAINST: 153 (0.0%)
Largest asset managers voting on “Election of Directors: Jeremy T. Grant” at Theravance Biopharma, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,032,7520 00For
BlackRock784,4090 00For
Fidelity784,1260 00For
Dimensional389,4820 00For
TIAA373,6580 00For
Charles Schwab294,8700 00For
Delaware/Macquarie208,7830 00For
Equitable139,8940 00For
American Century84,9710 00For
Columbia Threadneedle62,3110 00For
Lincoln Financial51,5250 00For
SEI42,8670 00For
Global X40,3310 00For
Northern Trust37,3150 00For
ALPS ETF Trust37,2070 00For
ETFis Series Trust I35,4260 00For
Goldman Sachs34,1620 00For
Nationwide30,2550 00For
T. Rowe Price27,1640 00For
QUANTITATIVE MASTER SERIES LLC26,3560 00For
AIG/SunAmerica18,5540 00For
Pacific Life18,3230 00For
GuideStone16,3560 00For
Bridge Builder Trust16,2830 00For
John Hancock14,6810 00For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

4. Election of Directors: Rick E Winningham

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-19.

Combines 2 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 28,586,164AGAINST: 1,965,694

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Rick E Winningham”): 28,586,164 for, 1,965,694 against, per its Form 8-K filed 2025-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,001,000 outstanding shares: 57% for, 4% against (61% of the company cast a for/against vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (5,694,134 for, 0 against).

FOR 100%
FOR: 5,694,134 (100.0%)
Largest asset managers voting on “Election of Directors: Rick E Winningham” at Theravance Biopharma, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,032,7520 00For
BlackRock784,4090 00For
Fidelity784,1260 00For
Dimensional389,4820 00For
TIAA373,6580 00For
Charles Schwab294,8700 00For
Delaware/Macquarie208,7830 00For
Equitable139,8940 00For
American Century84,9710 00For
Columbia Threadneedle62,3110 00For
Lincoln Financial51,5250 00For
SEI42,8670 00For
Global X40,3310 00For
Northern Trust37,3150 00For
ALPS ETF Trust37,2070 00For
ETFis Series Trust I35,4260 00For
Goldman Sachs34,1620 00For
Nationwide30,2550 00For
T. Rowe Price27,1640 00For
QUANTITATIVE MASTER SERIES LLC26,3560 00For
AIG/SunAmerica18,5540 00For
Pacific Life18,3230 00For
GuideStone16,3560 00For
Bridge Builder Trust16,2830 00For
John Hancock14,6810 00For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

5. Election of Directors: Susannah Gray

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-19.

Combines 2 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 39,943,074AGAINST: 110,833

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Susannah Gray”): 39,943,074 for, 110,833 against, per its Form 8-K filed 2025-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,001,000 outstanding shares: 80% for, 0.3% against (80% of the company cast a for/against vote).

The 41 asset managers below cast 99.9% of the shares they voted on this item FOR (5,690,536 for, 3,598 against).

FOR 99.9%
FOR: 5,690,536 (99.9%)AGAINST: 3,598 (0.1%)
Largest asset managers voting on “Election of Directors: Susannah Gray” at Theravance Biopharma, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,032,7520 00For
BlackRock784,4090 00For
Fidelity784,1260 00For
Dimensional389,4820 00For
TIAA373,6580 00For
Charles Schwab294,8700 00For
Delaware/Macquarie208,7830 00For
Equitable139,8940 00For
American Century84,9710 00For
Columbia Threadneedle62,3110 00For
Lincoln Financial51,5250 00For
SEI42,8670 00For
Global X40,3310 00For
Northern Trust37,3150 00For
ALPS ETF Trust37,2070 00For
ETFis Series Trust I35,4260 00For
Goldman Sachs34,1620 00For
Nationwide30,2550 00For
T. Rowe Price27,1640 00For
QUANTITATIVE MASTER SERIES LLC26,3560 00For
AIG/SunAmerica18,5540 00For
Pacific Life18,3230 00For
GuideStone16,3560 00For
Bridge Builder Trust16,2830 00For
John Hancock14,6810 00For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

6. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THERAVANCE BIOPHARMA, INC.'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATED

Meeting held 2025-05-19.

99.9% fund support · no official result

FOR 99.9%

The 40 asset managers below cast 99.9% of the shares they voted on this item FOR (5,674,027 for, 3,751 against).

FOR: 5,674,027 (99.9%)AGAINST: 3,751 (0.1%)
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THERAVANCE BIOPHARMA, INC.'S INDEPENDENT REGISTERED PUBLIC A” at Theravance Biopharma, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,032,7520 00For
BlackRock784,4090 00For
Fidelity784,1260 00For
Dimensional389,4820 00For
TIAA373,6580 00For
Charles Schwab294,8700 00For
Delaware/Macquarie208,7830 00For
Equitable139,8940 00For
American Century84,9710 00For
Columbia Threadneedle62,3110 00For
Lincoln Financial51,5250 00For
SEI42,8670 00For
Global X40,3310 00For
Northern Trust37,3150 00For
ALPS ETF Trust37,2070 00For
ETFis Series Trust I35,4260 00For
Goldman Sachs34,1620 00For
Nationwide30,2550 00For
T. Rowe Price27,1640 00For
QUANTITATIVE MASTER SERIES LLC26,3560 00For
AIG/SunAmerica18,5540 00For
Pacific Life18,3230 00For
Bridge Builder Trust16,2830 00For
John Hancock14,6810 00For
Brighthouse14,1220 00For

Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.

7. ADVISORY VOTE TO RATIFY NAMED EXECUTIVE OFFICERS' COMPENSATION

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-05-19.

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (317,476 for, 0 against).

FOR: 317,476 (100.0%)
Largest asset managers voting on “ADVISORY VOTE TO RATIFY NAMED EXECUTIVE OFFICERS' COMPENSATION” at Theravance Biopharma, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock283,8090 00For
JPMorgan17,3110 00For
GuideStone16,3560 00For

8. To vote on a non-binding advisory resolution regarding the compensation of Theravance Biopharma Inc.'s named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-05-08 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (123 for, 0 against).

FOR: 123 (100.0%)
Largest asset managers voting on “To vote on a non-binding advisory resolution regarding the compensation of Theravance Biopharma Inc.'s named e” at Theravance Biopharma, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
COLDSTREAM CAPITAL MANAGEMENT INC1230 00For
Echo45 Advisors LLC00 00--

Largest Theravance Biopharma, Inc. shareholders voting in 2024-2025

Ranked by the number of Theravance Biopharma, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 50,001,000 shares outstanding at the time of that meeting.

Top Theravance Biopharma, Inc. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1Madison Avenue Partners, LP 19.02%
2Weiss Asset Management LP 14.91%
3Newtyn Management, LLC 12.62%
4Irenic Capital Management LP 5.03%
5Vanguard 4.12%
6BlackRock 3.99%
7Park West Asset Management LLC 3.61%
8Camber Capital Management LP 2.00%
9State Street 1.95%
10GEODE CAPITAL MANAGEMENT, LLC 1.73%

Reported Theravance Biopharma, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Theravance Biopharma, Inc. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
Madison Avenue Partners, LP 19.02% DEF14A
Weiss Asset Management LP 14.91% 13D
Newtyn Management, LLC 8.60% 13G
BlackRock 6.90% 13F
Irenic Capital Management LP 5.52% DEF14A
Vanguard Group 4.16% 13F
Rick E Winningham 3.52% DEF14A
State Street 2.13% 13F
D.E. Shaw 1.84% 13F
Geode Capital 1.78% 13F

Percentages above are of 50,001,000 shares outstanding, as reported by Theravance Biopharma, Inc. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Theravance Biopharma, Inc.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Theravance Biopharma, Inc.'s shareholder meeting held 2025-05-19, in the 2024-2025 proxy season, 135 asset managers reported how they voted in their SEC Form N-PX filings, covering 937 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Theravance Biopharma, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To vote on a non-binding advisory resolution regarding the compensation of our named executive… — the reporting funds cast 99% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Theravance Biopharma, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.